Pfizer Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Pfizer is a global biopharmaceutical company; its Biopharma business was its only reportable segment.
Financial performance and liquidity
- Revenue: $58.5 billion, down 42% from $100.3 billion in 2022. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally.
- Profit and EPS: Net income attributable to Pfizer common shareholders was $2.1 billion versus $31.4 billion in 2022. Reported diluted EPS was $0.37, down 93%; adjusted diluted EPS, a non-GAAP measure, was $1.84, down 72%.
- Costs and margins: Cost of sales was $25.0 billion, or 42.7% of revenue, compared with 34.2% in 2022. The higher ratio reflected COVID-19 product inventory charges and a less favorable sales mix. R&D expense was $10.7 billion, down 7%; selling, informational and administrative expense was $14.8 billion, up 8%.
- Cash flow: Operating cash flow was $8.7 billion, down 70% from $29.3 billion. Investing cash outflow was $32.3 billion, including $43.4 billion paid, net of acquired cash, for Seagen. Financing cash inflow was $26.1 billion. Capital expenditures were $3.9 billion.
- Liquidity: Year-end cash and cash equivalents were $2.9 billion and short-term investments were $9.8 billion, versus $0.4 billion and $22.3 billion, respectively, in 2022. Current assets were $43.3 billion and current liabilities $47.8 billion.
- Debt: Short-term borrowings, including current debt, were $10.4 billion and long-term debt was $61.5 billion, totaling approximately $71.9 billion, up from approximately $35.8 billion a year earlier. Pfizer issued $31 billion of long-term debt and $8 billion of commercial paper to help finance Seagen. Moody’s and S&P ended 2023 with long-term ratings of A2 and A, respectively, both with stable outlooks.
- Other financial items: Pfizer recorded a $1.1 billion tax benefit and a reported effective tax rate of negative 105.4%, affected by earnings mix and tax resolutions. Dividends declared were $1.65 per share for 2023.
Material changes versus 2022
- COVID-19 product sales fell sharply: Comirnaty revenue was $11.2 billion, down 70%, and Paxlovid revenue was $1.3 billion, down 93%.
- Paxlovid revenue included a $3.5 billion non-cash reversal related to the expected return of about 6.5 million U.S. government treatment courses. Pfizer also recorded $6.2 billion of non-cash inventory write-offs and related charges for Paxlovid and Comirnaty.
- Growth in other products included the Vyndaqel family (+36% to $3.3 billion), Eliquis (+5% operationally to $6.7 billion), and the Prevnar family (+3% operationally to $6.4 billion). Ibrance revenue declined 6% operationally to $4.8 billion.
- Income from continuing operations before tax fell to $1.1 billion from $34.7 billion, reflecting lower revenue, higher impairment and restructuring charges, and increased amortization and administrative expenses.
- Pfizer completed its $44.2 billion acquisition of Seagen on December 14, 2023. Seagen contributed $120 million of revenue during the reported period; its acquisition accounting remained provisional at year-end.
Outlook, management commentary and risks
- Management’s 2024 priorities include building oncology leadership, advancing pipeline innovation, maximizing new-product performance, expanding margins through cost realignment, and allocating capital to enhance shareholder value. The filing says 2024 COVID-19 product revenue is expected to be below 2023, with more than 80% of Comirnaty’s 2024 global revenue expected in the second half. It does not provide a clear full-year 2024 revenue or EPS guidance figure in the supplied filing text.
- The enterprise-wide Realigning our Cost Base program is expected to deliver at least $4 billion of net savings, primarily during 2023–2024; approximately $3 billion of program costs are expected through 2024. Pfizer also expects about $1 billion of annual Seagen cost synergies by 2026.
- Pfizer expects a moderate revenue impact from patent expirations in 2024–2025 and a more significant impact in 2026–2030. Eliquis is among the first medicines selected for Medicare price negotiation; the negotiated price is to take effect in 2026.
- The Rocky Mount, North Carolina manufacturing facility was damaged by a July 2023 tornado. Manufacturing resumed, but affected medicine supply may remain constrained through 2024. Pfizer recorded $286 million of related 2023 costs, partly offset by insurance recoveries.
- Key risks include uncertain demand and channel transition for COVID-19 products, patent challenges and generic competition, pricing and reimbursement pressure, R&D and regulatory uncertainty, Seagen integration and increased leverage, manufacturing and supply disruption, and legal, tax, cybersecurity and geopolitical exposures. Pfizer said it could not estimate the range of reasonably possible legal losses beyond amounts accrued.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The audit of internal controls excluded Seagen, which represented 22% of consolidated assets at year-end.
Investor facts to verify
- Reconcile the $3.5 billion Paxlovid revenue reversal, expected returns and U.S. patient-assistance supply arrangements with subsequent reported revenue and cash receipts.
- Track COVID-19 demand, inventory levels and write-offs, especially as sales shift from government contracts to commercial channels.
- Monitor Seagen integration, final purchase-price allocation, debt reduction, interest expense and progress toward the stated synergy target.
- Assess the assumptions behind the $4 billion cost-savings target and related restructuring charges, including execution and potential business disruption.
- Review patent litigation and exclusivity developments, Medicare negotiation implementation, and the expected effects of product expirations and pricing changes.
- Follow Rocky Mount supply recovery, additional costs or insurance recoveries, and any material developments in legal, tax or other contingencies.